Table 4.

NLA Considerations for Screening and Diagnosis of FH^a, 26

Children, Adolescents, Young Adults <20 y Old	Adults ≥20 y Old
LDL‐C ≥160 mg/dL (4.1 mmol/L) Non‐HDL‐C ≥190 mg/dL (4.9 mmol/L)	LDL‐C ≥190 md/dL (4.9 mmol/L) Non‐HDL ≥220 mg/dL (5.7 mmol/L)
At the LDL‐C levels listed below, the probability of FH is ≈80% in the setting of general population screening. These LDL‐C levels should prompt the clinician to strongly consider a diagnosis of FH and obtain further family information:
LDL‐C ≥250 mg/dL (6.5 mmol/L) in a patient aged ≥30 y
LDL‐C >220 mg/dL (5.7 mmol/L) for patients aged 20 to 29 y
LDL‐C ≥190 mg/dL (4.9 mmol/L) in patients aged <20 y

FH indicates familial hypercholesterolemia; HDL, high‐density lipoprotein; LDL‐C, low‐density lipoprotein cholesterol; MEDPED, Make Early Diagnosis to Prevent Early Death; NLA, National Lipid Association; PCSK9, proprotein convertase subtilisin/kexin 9.

^aThe NLA expert statement was not intended to be a substitute for the MEDPED, Dutch Lipid Clinic Network (DLCN), or Simon Broome criteria. In addition, the NLA recommends use of MEDPED, DLCN, and Simon Broome criteria for diagnosis of FH.